Spyre Therapeutics
SYRE
70 hedge funds and large institutions have $95.8M invested in Spyre Therapeutics in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
3% more funds holding
Funds holding: 68 → 70 (+2)
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
0.02% less ownership
Funds ownership: 2.85% → 2.83% (-0.02%)
39% less capital invested
Capital invested by funds: $158M → $95.8M (-$62M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$680K |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$533K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$271K |
| 4 |
D.E. Shaw & Co
New York
|
+$185K |
| 5 |
Renaissance Technologies
New York
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$611K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$415K |
| 3 |
Man Group
London,
United Kingdom
|
-$315K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$303K |
| 5 |
Morgan Stanley
New York
|
-$222K |
SYRE Hedge Fund Activity: Q1 2020 in Review
70 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2020, worth a combined $95.8M — down 39% from $158M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SYRE positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 22 trimmed.
The largest buyer was Artal Group, adding an estimated $680K. The largest seller was Russell Investments Group, cutting an estimated $611K.
- 70 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2020, up from 68 in Q4 2019.
- Funds reported $95.8M of Spyre Therapeutics stock for Q1 2020, down 39% quarter-over-quarter.
- 9 funds opened new Spyre Therapeutics positions in Q1 2020 and 6 closed out, a net change of +3 holders.
- The largest Spyre Therapeutics buyer in Q1 2020 was Artal Group, an estimated $680K added.
- The largest Spyre Therapeutics seller in Q1 2020 was Russell Investments Group, an estimated $611K sold.
Based on aggregated 13F filings for Q1 2020.